Federal Register / Vol. 89, No. 185 / Tuesday, September 24, 2024 / Notices 77865 

that the public interest did not require 

consideration of the matters in a 

meeting open to public observation; and 

that the matters could be considered in 

a closed meeting by authority of 

subsections (c)(2) and (c)(6), of the 

‘‘Government in the Sunshine Act’’ (5 

U.S.C. 552b (c)(2) and(c)(6)). 

CONTACT PERSON FOR MORE INFORMATION: 

Requests for further information 

concerning the meeting may be directed 

to Debra A. Decker, Executive Secretary 

of the Corporation, at 202–898–8748. 

Dated this the 20th day of September, 

2024. 

Federal Deposit Insurance Corporation. 

James P. Sheesley, 

Assistant Executive Secretary. 

[FR Doc. 2024–22010 Filed 9–20–24; 4:15 pm] 

BILLING CODE 6714–01–P 

FEDERAL MINE SAFETY AND HEALTH 

REVIEW COMMISSION 

Sunshine Act Meetings 

TIME AND DATE: 2 p.m., Tuesday, 

September 24, 2024. 

PLACE: The Richard V. Backley Hearing 

Room, Room 511, 1331 Pennsylvania 

Avenue NW, Suite 504 North, 

Washington, DC 20004 (enter from F 

Street entrance). 

STATUS: Open. 

MATTERS TO BE CONSIDERED: The 

Commission will consider and act upon 

the following in open session: Geneva 

Rock Products, Inc., Docket No. WEST 

2022–0097. (Issues include whether the 

Judge abused his discretion when he 

ordered a stay of the case for an 

indefinite duration because of a pending 

criminal matter.) 

Any person attending this meeting 

who requires special accessibility 

features and/or auxiliary aids, such as 

sign language interpreters, must inform 

the Commission in advance of those 

needs. Subject to 29 CFR 2706.150(a)(3) 

and 2706.160(d). 

CONTACT PERSON FOR MORE INFO: 

Emogene Johnson (202) 434–9935/(202) 

708–9300 for TDD Relay/1–800–877– 

8339 for toll free. 

PHONE NUMBER FOR LISTENING TO

MEETING: 1–(866) 236–7472, Passcode: 

678–100. 

Authority: 5 U.S.C. 552b. 

Dated: September 20, 2024. 

Sarah L. Stewart, 

Deputy General Counsel. 

[FR Doc. 2024–22012 Filed 9–20–24; 4:15 pm] 

BILLING CODE 6735–01–P 

FEDERAL RESERVE SYSTEM 

Change in Bank Control Notices; 

Acquisitions of Shares of a Bank or 

Bank Holding Company 

The notificants listed below have 

applied under the Change in Bank 

Control Act (Act) (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire shares of a bank 

or bank holding company. The factors 

that are considered in acting on the 

applications are set forth in paragraph 7 

of the Act (12 U.S.C. 1817(j)(7)). 

The public portions of the 

applications listed below, as well as 

other related filings required by the 

Board, if any, are available for 

immediate inspection at the Federal 

Reserve Bank(s) indicated below and at 

the offices of the Board of Governors. 

This information may also be obtained 

on an expedited basis, upon request, by 

contacting the appropriate Federal 

Reserve Bank and from the Board’s 

Freedom of Information Office at 

https://www.federalreserve.gov/foia/ 

request.htm. Interested persons may 

express their views in writing on the 

standards enumerated in paragraph 7 of 

the Act. 

Comments received are subject to 

public disclosure. In general, comments 

received will be made available without 

change and will not be modified to 

remove personal or business 

information including confidential, 

contact, or other identifying 

information. Comments should not 

include any information such as 

confidential information that would not 

be appropriate for public disclosure. 

Comments regarding each of these 

applications must be received at the 

Reserve Bank indicated or the offices of 

the Board of Governors, Ann E. 

Misback, Secretary of the Board, 20th 

Street and Constitution Avenue NW, 

Washington DC 20551–0001, not later 

than October 9, 2024. 

A. Federal Reserve Bank of Cleveland 

(Nadine M. Wallman, Vice President) 

1455 East Sixth Street Cleveland, Ohio 

44101–2566. Comments can also be sent 

electronically to 

Comments.applications@clev.frb.org: 

1. Larry T. Clark, Danville, Kentucky, 

as Successor Trustee of the John M. St. 

Clair, Jr. Trust dated January 16, 2006; 

to retain voting shares of Citizens 

Guaranty Financial Corporation, Irvine, 

Kentucky, and thereby indirectly retain 

voting shares of Citizens Guaranty Bank, 

Richmond, Kentucky. 

B. Federal Reserve Bank of Chicago 

(Colette A. Fried, Assistant Vice 

President) 230 South LaSalle Street, 

Chicago, Illinois 60690–1414. 

Comments can also be sent 

electronically to 

Comments.applications@chi.frb.org: 

1. Bradley C. Hanson, Sioux Falls, 

South Dakota; to acquire voting shares 

of AgCom Holdings, Inc., and thereby 

indirectly acquire voting shares of 

Maxwell State Bank, both of Maxwell, 

Iowa. 

2. Stephen Lange Ranzini Inherited 

IRA, Stephen Lange Ranzini, trustee, 

both of Ann Arbor, Michigan; Joseph 

Lange Ranzini IRA, Joseph Lange 

Ranzini, trustee, both of Waynesboro, 

Virginia; Paul Lange Ranzini, Meunster, 

Germany; David William Ranzini, 

Tokyo, Japan; Gregory Paul Ranzini, 

Wilmington, Delaware; Holly Ann Clare, 

Atlanta, Georgia; Emily Elizabeth Hu, 

Washington, DC; and Jonathan Paul Hu 

and Abigail Raffaela Hu, both of 

Princeton, New Jersey; to join the 

Ranzini Family Group, a group acting in 

concert, to retain voting shares of 

University Bancorp, Inc., and thereby 

indirectly retain voting shares of 

University Bank, both of Ann Arbor, 

Michigan. 

Board of Governors of the Federal Reserve 

System. 

Michele Taylor Fennell, 

Associate Secretary of the Board. 

[FR Doc. 2024–21815 Filed 9–23–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifiers: CMS–10516] 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 

(PRA), Federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, and to allow 

a second opportunity for public 

comment on the notice. Interested 

persons are invited to send comments 

regarding the burden estimate or any 


lotter on DSK11XQN23PROD with NOTICES1
77866 Federal Register / Vol. 89, No. 185 / Tuesday, September 24, 2024 / Notices 

other aspect of this collection of 

information, including the necessity and 

utility of the proposed information 

collection for the proper performance of 

the agency’s functions, the accuracy of 

the estimated burden, ways to enhance 

the quality, utility, and clarity of the 

information to be collected, and the use 

of automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

DATES: Comments on the collection(s) of 

information must be received by the 

OMB desk officer by October 24, 2024. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, please access the CMS PRA 

website by copying and pasting the 

following web address into your web 

browser: https://www.cms.gov/ 

Regulations-and-Guidance/Legislation/ 

PaperworkReductionActof1995/PRAListing. 

FOR FURTHER INFORMATION CONTACT: 

William Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. The term ‘‘collection of 

information’’ is defined in 44 U.S.C. 

3502(3) and 5 CFR 1320.3(c) and 

includes agency requests or 

requirements that members of the public 

submit reports, keep records, or provide 

information to a third party. Section 

3506(c)(2)(A) of the PRA (44 U.S.C. 

3506(c)(2)(A)) requires federal agencies 

to publish a 30-day notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension or 

reinstatement of an existing collection 

of information, before submitting the 

collection to OMB for approval. To 

comply with this requirement, CMS is 

publishing this notice that summarizes 

the following proposed collection(s) of 

information for public comment: 

1. Type of Information Collection 

Request: Extension of a currently 

approved collection; Title of 

Information Collection: Program 

Integrity: Exchange, Premium 

Stabilization Programs, and Market 

Standards; Amendments to the HHS 

Notice of Benefit and Payment 

Parameters for 2014; Final Rule II; Use: 

On March 23, 2010, the Patient 

Protection and Affordable Care Act 

(PPACA; Pub. L. 111–148) was signed 

into law and on March 30, 2010, the 

Health Care and Education 

Reconciliation Act of 2010 (Pub. L. 111– 

152) was signed into law. The two laws 

implement various health insurance 

policies. On June 19, 2013, the 

Department of Health and Human 

Services (HHS) published proposed rule 

CMS–9957–P: Program Integrity: 

Exchanges, SHOP, Premium 

Stabilization Programs, and Market 

Standards (78 FR 37302) (Program 

Integrity Proposed Rule) which, among 

other things, contained third party 

disclosure requirements and data 

collections that supported the oversight 

of premium stabilization programs, 

State Exchanges, and qualified health 

plan (QHP) issuers in Federallyfacilitated Exchanges (FFEs). Parts of the 

proposed rule were finalized as Patient 

Protection and Affordable Care Act; 

Program Integrity: Exchange, Premium 

Stabilization Programs, and Market 

Standards; Amendments to the HHS 

Notice of Benefit and Payment 

Parameters for 2014; Final Rule 

(Program Integrity Final Rule II), 78 FR 

25326 (October 24, 2013). This ICR 

relates to a portion of the information 

collection request (ICR) requirements set 

forth in the final rule. Form Number: 

CMS–10516 (OMB control number: 

0938–1277); Frequency: Annually; 

Affected Public: Private Sector, State, 

Local, or Tribal Governments; Business 

or other for-profits, and Not-for-Profits; 

Number of Respondents: 457; Number 

of Responses: 457; Total Annual Hours: 

42,771. (For questions regarding this 

collection, contact Andrea Honig at 

(301) 492–4147.) 

William N. Parham, III, 

Director, Division of Information Collections 

and Regulatory Impacts, Office of Strategic 

Operations and Regulatory Affairs. 

[FR Doc. 2024–21732 Filed 9–23–24; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2015–E–2079] 

Determination of Regulatory Review 

Period for Purposes of Patent 

Extension; BRAVECTO; Correction 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; correction. 

SUMMARY: The Food and Drug 

Administration (FDA or the Agency) 

published a notice in the Federal 

Register of February 12, 2018, for the 

determination of the regulatory review 

period for the animal drug BRAVECTO. 

In accordance with the Court’s order in 

Nissan Chemical Corp., et al. v. FDA, et 

al., No. 22–01598 (D.D.C), this 

document revises the SUPPLEMENTARY

INFORMATION section of that notice by 

adjusting the start date of the testing 

phase for BRAVECTO. This notice 

supersedes the June 11, 2021, Federal 

Register document revising the 

February 12, 2018, notice. 

FOR FURTHER INFORMATION CONTACT: 

Beverly Friedman, Office of Regulatory 

Policy, Food and Drug Administration, 

10903 New Hampshire Ave., Bldg. 51, 

Rm. 6250, Silver Spring, MD 20993, 

301–796–3600. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of February 12, 2018 

(83 FR 6033), in FR Doc. 2018–02761, in 

the first column, the first two 

paragraphs under the section ‘‘II. 

Determination of Regulatory Review 

Period,’’ the following revision is made 

on page 6034: 

FDA has determined that the 

applicable regulatory review period for 

BRAVECTO is 1,548 days. Of this time, 

1,510 days occurred during the testing 

phase of the regulatory review period, 

while 38 days occurred during the 

approval phase. These periods of time 

were derived from the following dates: 

1. The date an exemption under 

section 512(j) of the Federal Food, Drug, 

and Cosmetic Act (FD&C Act) (21 U.S.C. 

360b(j)) became effective: February 19, 

2010. Pursuant to the Court’s order in 

Nissan Chemical Corp., et al. v. FDA, et 

al., No. 22–01598 (D.D.C), the start date 

of the testing phase for BRAVECTO was 

February 19, 2010. 

Dated: September 19, 2024. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2024–21841 Filed 9–23–24; 8:45 am] 

BILLING CODE 4164–01–P 


lotter on DSK11XQN23PROD with NOTICES1